

Promore Pharma informs about the last day of trading to receive subscription rights

STOCKHOLM, 27 May, 2021 — The record date to qualify for the right to subscription rights in the announced capital raising is 1 June 2021. This means that the last day of trading in Promore Pharma's share, including the right to receive a subscription right for each existing share, is tomorrow 28 May 2021.

On May 7, 2021, Promore Pharma announced that the Board of Directors has resolved to raise capital through a fully guaranteed rights issue of approximately SEK 48.6 million, subject to the Extraordinary General Meeting approving the Board's decision. At the Extraordinary General Meeting today, 27 May 2021, the Board's resolution was approved, and Promore Pharma hereby informs that the record date to qualify for the right to subscription rights in the rights issue is 1 June 2021. This means that the last day of trading in Promore Pharma's share, including the right to receive a subscription right share is tomorrow, May 28, 2021.

For additional information, please contact

Jonas Ekblom, CEO

Phone: [+46] 736 777 540

E-mail: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO

Phone: [+46] 708 565 245

E-mail: erik.magnusson@promorepharma.com

Promore Pharms Certified Adviser is Erik Penser Bank

Tel: [+46] 8-463 83 00

E-mail: certifiedadviser@penser.se

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogenous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetic scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.

Attachments

[Promore Pharma informs about the last day of trading to receive subscription rights](#)